Reviva Pharmaceuticals Holdings, Inc. (RVPH)
| Market Cap | 7.06M -76.4% |
| Revenue (ttm) | n/a |
| Net Income | -13.02M |
| EPS | -1.75 |
| Shares Out | 13.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,144 |
| Open | 0.5100 |
| Previous Close | 0.5300 |
| Day's Range | 0.5000 - 0.5550 |
| 52-Week Range | 0.2620 - 17.2000 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 17.50 (+3,149.77%) |
| Earnings Date | Nov 13, 2026 |
About RVPH
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of demen... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for RVPH stock is "Strong Buy" and the 12-month stock price target is $17.5.
News
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 -
Reviva Pharmaceuticals Holdings Quarterly report: Q2 2026
Reviva Pharmaceuticals Holdings has published its Q2 2026 quarterly earnings report on August 12, 2026.
Reviva Pharmaceuticals Holdings Earnings release: Q2 2026
Reviva Pharmaceuticals Holdings released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Reviva Pharmaceuticals Holdings Transcript: Life Sciences Virtual Investor Forum
Brilaroxazine showed robust, durable efficacy and a favorable safety profile in phase III trials for schizophrenia, outperforming historical antipsychotics and addressing key unmet needs. A second phase III trial is planned, with NDA submission targeted for 2028 and potential exclusivity to 2046.
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...
Reviva Pharmaceuticals Holdings Transcript: Lytham Partners Spring 2026 Investor Conference
Brilaroxazine showed robust, sustained efficacy and safety in phase III schizophrenia trials, with minimal relapse and superior differentiation versus current antipsychotics. A second confirmatory trial is planned, with NDA filing targeted for early 2028 and potential patent exclusivity to 2046.
Reviva Pharmaceuticals Holdings Transcript: A.G.P.'s Annual Virtual Healthcare Conference
Brilaroxazine is advancing to a pivotal phase III trial for schizophrenia, with a new formulation designed to extend patent life to 2046. Pending FDA feedback, the company aims to expand indications and regain Nasdaq compliance, supported by a strong financial position and major upcoming catalysts.
Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Holdings Slides: Corporate presentation
Reviva Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 16, 2026.
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form ...
Reviva Pharmaceuticals Holdings Transcript: Study update
Brilaroxazine is advancing to a second phase III trial in schizophrenia, with a new formulation aimed at extending patent life to 2046. FDA feedback on the formulation switch is expected mid-year, and the trial is set to start in Q3, leveraging strong prior data and a solid financial runway.
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia –
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the t...
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
– Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European...
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...
Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights
– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial–
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Bril...
Reviva Pharmaceuticals Holdings Transcript: Lytham Partners Spring 2025 Investor Conference
Brilaroxazine, in phase III for schizophrenia, showed robust efficacy for both primary and negative symptoms, superior adherence, and a favorable safety profile. Full data is expected in Q2 2025, with NDA submission targeted for end of 2026.
Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
– 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment –